<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>PopVax is Awarded 2 Million USD as One of the Winners of the BARDA Patch Forward Prize for its Seasonal Influenza Vaccine built on a Novel mRNA-encoded Immunogen Display Architecture Delivered via Dissolvable Microarray Patch</title>
    <link>https://www.taxtmi.com/news?id=30214</link>
    <description>PopVax was awarded a BARDA Concept Stage Patch Forward Prize to accelerate a seasonal influenza vaccine that integrates an mRNA encoded immunogen display architecture and LNP platform with a dissolvable microarray patch. The collaboration with LTS Lohmann pairs PopVax&#039;s GMP mRNA LNP production and machine learning immunogen design with LTS&#039;s microarray patch manufacturing to enable thermostable, self administered, dissolvable microneedle delivery, support rapid response warm base manufacturing, and advance preclinical development of broadly protective influenza vaccine candidates.</description>
    <language>en-us</language>
    <pubDate>Tue, 14 Jan 2025 12:16:03 +0530</pubDate>
    <lastBuildDate>Tue, 14 Jan 2025 12:16:03 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=788755" rel="self" type="application/rss+xml"/>
    <item>
      <title>PopVax is Awarded 2 Million USD as One of the Winners of the BARDA Patch Forward Prize for its Seasonal Influenza Vaccine built on a Novel mRNA-encoded Immunogen Display Architecture Delivered via Dissolvable Microarray Patch</title>
      <link>https://www.taxtmi.com/news?id=30214</link>
      <description>PopVax was awarded a BARDA Concept Stage Patch Forward Prize to accelerate a seasonal influenza vaccine that integrates an mRNA encoded immunogen display architecture and LNP platform with a dissolvable microarray patch. The collaboration with LTS Lohmann pairs PopVax&#039;s GMP mRNA LNP production and machine learning immunogen design with LTS&#039;s microarray patch manufacturing to enable thermostable, self administered, dissolvable microneedle delivery, support rapid response warm base manufacturing, and advance preclinical development of broadly protective influenza vaccine candidates.</description>
      <category>News</category>
      <law>-</law>
      <pubDate>Tue, 14 Jan 2025 12:16:03 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/news?id=30214</guid>
    </item>
  </channel>
</rss>